Spalbend 25 & 100 25 mg, 100 mg Tablet
PDF Leaflet Revision Date: 24 January 2023
Clinical Summary
Quick overview from the medicine insert
Indication
First-line treatment for specific hematological malignancies.
Dosage (summary)
100 mg/mu00b2 on days 1 and 2 for CLL; 90 mg/mu00b2 with rituximab for NHL; 120-150 mg/mu00b2 for multiple myeloma.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; teratogenic effects.
Key Drug Interactions
- CYP1A2 inhibitors
- Myelosuppressive agents
- Ciclosporin
- Tacrolimus
Contraindications
- Hypersensitivity
- Severe hepatic impairment
- Severe bone marrow suppression
- Pregnancy
- Lactation
Common side effects
- Leukopenia
- Thrombocytopenia
- Nausea
- Vomiting
- Skin reactions
Counselling Points
- Avoid pregnancy during treatment
- Monitor for signs of infection
- Report severe skin reactions
- Avoid driving if experiencing ataxia or somnolence
Serious warnings
- Myelosuppression
- Infection risk
- Anaphylaxis
- Tumor lysis syndrome
Important Disclaimer
The Spalbend 25 & 100 25 mg, 100 mg Tablet professional information leaflet below is the property of Ruby Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
